✦ LIBER ✦

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

✍ Scribed by Cufer, T.; Vrdoljak, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line therapy with gefitinib in co

✍ G. Robinet; F. Barlesi; P. Fournel; H. Berard; R. Corre; A. Vergnenegre; L. Falc 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 160 KB

O-4 A randomized phase II study of docet

✍ Groen, H.J.M.; Wachters, F.M.; Biesma, B.; Schramel, F.M.N.H.; Stigt, J.A.; Smit 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Open, Randomized, Phase II Study of Sing

✍ Christian Manegold; Gabriele Koschel; Dagmar Hruska; Kathrin Schott-von-Römer; J 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 155 KB

O-091 A randomized phase II trial of doc

✍ Robinet, G.; Falchero, L.; Perol, M.; Thomas, P.; Monnet, I.; Grivaux, M.; Crequ 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Irinotecan and docetaxel as first line c

✍ Raez, Luis E; Rosado, Manuel F; Santos, Edgardo S; Reis, Isildinha M 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 54 KB

P-588 Biweekly docetaxel and vinorelbine

✍ Vázquez, S.; Villanueva, M.; Amenedo, M.; Firvida, J.; Lázaro, M.; Del Río, L.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB